Melanoma Archives

msd cancer research uk monash crt merck australia

News and Trends 1 Feb 2016

New Discovery unites Australia, Germany and UK Against Blood Cancers

Cancer Research UK has teamed up with MSD (Merck) and the Wellcome Trust to co-develop some Inhibitors for both Cancerous and Non-cancerous blood disorders from the Australian Academia-Biotech Network. The Australian Co-operative Research Centre (CRC) for Cancer Therapeutics (CTx) in Melbourne has a range of investigational inhibitors for blood disorders – including Leukemia. CTx is collaborative partnership […]

February 1, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 25 Jan 2016

This Potential First in Class Cancer Therapy Could Help Patients Avoid Eye Surgery

Immunocore in Oxford (UK) has been Granted Orphan Drug Designation for a Phase I Super rare Eye cancer drug by the FDA. Uveal melanoma is a rare disease in which cancer cells form in the tissues of the eye, and comprises approximately 3% of all melanomas. It is actually the primary intraocular malignancy of the adult eye and currently, […]

January 25, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 26 Sep 2015

Replimune smashes Oncolytic viral €26.8M series A financing round

Replimune is an Oxford (UK) biotech baby, having only been founded in April this year a spin-off of former US BioVex. Nonetheless, this hasn’t stopped its Series A finance round reaching up to €26.8M. Replimune’s focal research is in developing new immuno-oncology therapies using oncolytic viruses, inspired by BioVex-Amgen’s T-VEC success. Replimune was founded by […]

September 26, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 17 Jul 2015

TC BioPharm raises €1.7M to commence treatment in UK cancer patients

TC BioPharm raised €1.7M (£1.18) to treat UK-based patients with melanoma, lung and kidney cancer. Thanks to this funding, the Phase I/II clinical studies will start as of September in several parts of the country. TC BioPharm’s lead product, ImmuniCell, uses patients’ own cells grown in culture to target a wide variety of different cancers. […]

July 17, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 3 Jul 2015

Lilly Cooperates with Immunocore to Fight Skin Cancer

Eli Lilly expands its portfolio in immune-oncology therapies. This time, Immunocore‘s lead T cell receptor-based drug, IMCgp100 is tested in combination with Lilly’s kinase inhibitors galunisertib and merestinib. This second collaboration between these two companies aims to increase drug efficacy against melanoma cancer. Melanomas are rare forms of skin cancer, that have a high potential […]

July 3, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 18 Apr 2015

Another Partnership between Immunocore and MedImmune against Skin Cancer

Immunocore Limited, a world-leading biotechnology company developing novel biological drugs to treat cancer and other diseases, and MedImmune, the global biologics research and development arm of AstraZeneca have just entered into a second effective collaboration for a potential skin cancer treatment. It concerns melanoma which is a form of skin cancer that accounts for less than five per cent of […]

April 18, 2015 - 2 minutesmins - By Julie Lellouche

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us